Monitoring Phenytoin Levels with Concurrent Valproic Acid Use
When phenytoin and valproic acid are used together, you must measure or calculate free (unbound) phenytoin levels rather than relying on total phenytoin levels, as valproic acid significantly increases the free fraction of phenytoin through protein displacement and metabolic inhibition.
The Critical Drug Interaction
Valproic acid displaces phenytoin from plasma albumin binding sites and inhibits its hepatic metabolism. Coadministration increases the free fraction of phenytoin by approximately 60%, while total plasma clearance and apparent volume of distribution of phenytoin increase by 30% 1. This means total phenytoin levels become unreliable indicators of therapeutic effect or toxicity.
Monitoring Strategy
Preferred Approach: Direct Measurement
- Measure free (unbound) phenytoin levels directly whenever this assay is available
- Target therapeutic range for free phenytoin: 1-2 mcg/mL (compared to 10-20 mcg/mL for total phenytoin in patients not on valproic acid)
- Free phenytoin measurement is the gold standard and avoids estimation errors 2, 3
Alternative: Calculation When Direct Measurement Unavailable
If free phenytoin assays are not readily available, use the Haidukewych equation for estimation:
Free phenytoin (mcg/mL) = 0.095 × Total phenytoin + 0.001 × Valproic acid × Total phenytoin
(All concentrations in mcg/mL)
This equation demonstrates the least bias and most precision compared to alternatives 2. The May equation consistently underpredicts free phenytoin concentrations and should be avoided.
Important Caveats About Calculations
- Prediction equations have significant limitations, particularly in critically ill patients where mean differences between actual and estimated free phenytoin can exceed 0.8 mcg/mL 3
- ICU patients show greater discrepancies than non-ICU patients
- Hypoalbuminemia (common in critically ill patients) further increases free drug concentrations 4
- Even with the best equation, the free phenytoin fraction is not constant and usually exceeds the expected 10% in patients comedicated with valproic acid 2
Clinical Monitoring Algorithm
- Obtain baseline measurements: Total phenytoin, valproic acid, and albumin levels
- If free phenytoin assay available: Measure directly and target 1-2 mcg/mL
- If free phenytoin assay unavailable:
- Use Haidukewych equation for estimation
- Consider albumin levels in interpretation (hypoalbuminemia increases free fraction)
- Monitor closely for clinical signs of toxicity regardless of calculated values
- Adjust phenytoin dosage based on clinical response and free (not total) phenytoin levels 1
- Monitor frequently after any dose changes or changes in valproic acid dosing
Critical Warning Signs
Watch for breakthrough seizures despite "therapeutic" total phenytoin levels—this may indicate the combination is ineffective 1. Conversely, 57% of patients may have supratherapeutic free phenytoin levels even when total levels appear within normal range 4.
Signs of phenytoin toxicity include ataxia, nystagmus, diplopia, and altered mental status 5. These can occur even with "normal" total phenytoin levels when valproic acid is present.
Method-Specific Considerations
The accuracy of predictive equations depends on the analytical method used. HPLC measurements provide more accurate predictions than standard TDx assays, which tend to yield higher total and free phenytoin concentrations 6. Ensure consistency in laboratory methodology when monitoring over time.